

June 30, 2023

Contents

Clinical Profile Documentation	2
Updates	2
AJCC 8th Edition Staging	2
Problem Groups	2
Additions	2
Problems	2
Additions	2
Problem & Codes Summary	2
Lab Analytes & Panels	4
Additions and Updates	4
Medications	5
Additions	5
Updates	5
Regimen Library	6
Additions	6
Biosimilar Addition	6
Updates	6
Research	7
Updates	7
Billing & HCPCS Codes	8
Updates	8
HCPCS & NDC Crosswalk	10
Additions	10

Clinical Profile Documentation

Updates

AJCC 8th Edition Staging

This release contains updates to align with the St. Jude modification of the Ann Arbor system to the Lugano Classification system for the following problem groups:

- **Lymphoma, Non-Hodgkin (NHL), Lymphoblastic**
- **Lymphoma, Non-Hodgkin (NHL), Burkitt's**

The staging row will display updated **Stage** values based on the changes. The new content does not affect previous charting documented on existing patients. All previous charting is brought forward during a subsequent visit, just as it did prior to this release.

Lymphoma, Non-Hodgkin (NHL), Lymphoblastic and **Lymphoma, Non-Hodgkin (NHL), Burkitt's** staging row will display updated **Stage** values based on the changes. The following documentation points have changed:

- **New Stage Values:** I, IE, II, IIE, II bulky*, III, IV
- **Removed Stage Values:** IIR, IIIA, IIIB

Problem Groups

Additions

Mammary invasive carcinoma is now available for **Breast cancer, Histopathologic Type**.

Malignant melanoma of uveal tract (disorder) has been added to **Melanoma, Uvea**, and **Ciliary Body/Choroid** problem groups.

Problems

Additions

New items are available for documentation in **Problems** and appear in **Charge Capture Report (CCR)**.

Problem & Codes Summary

Problem	ICD-10 Codes
Difficulty eating due to fatigue (finding)	<ul style="list-style-type: none"> • R53.83 Other fatigue • R63.30 Feeding difficulties, unspecified
Deep vein thrombosis (DVT)	<ul style="list-style-type: none"> • I82 category
Energy and stamina finding (finding)	<ul style="list-style-type: none"> • R53.83 Other fatigue
Excessive postexertional fatigue (finding)	<ul style="list-style-type: none"> • R53.83 Other fatigue
Exhausted on least exertion (finding)	<ul style="list-style-type: none"> • R53.83 Other fatigue • R54 Age-related physical debility
Exhaustion (finding)	<ul style="list-style-type: none"> • R53.83 Other fatigue
Extreme exhaustion (finding)	<ul style="list-style-type: none"> • R53.83 Other fatigue
Fatigability (finding)	<ul style="list-style-type: none"> • R53.83 Other fatigue
Fatigue with acquired immunodeficiency syndrome (disorder)	<ul style="list-style-type: none"> • B20 Human immunodeficiency virus [HIV] disease • R53.83 Other fatigue
Finding of general energy (finding)	<ul style="list-style-type: none"> • R53.83 Other fatigue • R54 Age-related physical debility
Finding of general stamina (finding)	<ul style="list-style-type: none"> • R53.83 Other fatigue
Functional quadriplegia (disorder)	<ul style="list-style-type: none"> • R53.2 Functional quadriplegia
Functional quadriplegia due to multiple sclerosis (disorder)	<ul style="list-style-type: none"> • G35 Multiple sclerosis • R53.2 Functional quadriplegia
General problem AND/OR complaint (finding)	<ul style="list-style-type: none"> • Z78.9 Other specified health status
Generally unwell (finding)	<ul style="list-style-type: none"> • R69 Illness, unspecified
Infectious disease (disorder)	<ul style="list-style-type: none"> • B99.9 Unspecified infectious disease
Screening for Lung Cancer	<ul style="list-style-type: none"> • Z12.2 - Encounter for screening for malignant neoplasm of respiratory organs
Seizure disorder (disorder)	<ul style="list-style-type: none"> • R56.9 Unspecified convulsions
Sensation of heaviness in limbs (finding)	<ul style="list-style-type: none"> • R29.898 Other symptoms and signs involving the musculoskeletal system
Tired (finding)	<ul style="list-style-type: none"> • P96.89 Other specified conditions originating in the perinatal period • R53.83 Other fatigue
Tired all the time (finding)	<ul style="list-style-type: none"> • R53.82 Other fatigue
Tired on least exertion (finding)	<ul style="list-style-type: none"> • R53.83 Other fatigue
Tires quickly (finding)	<ul style="list-style-type: none"> • R53.83 Other fatigue
Underactive infant (finding)	<ul style="list-style-type: none"> • R53.83 Other fatigue
Underexertion (finding)	<ul style="list-style-type: none"> • R53.83 Other fatigue

Problem	ICD-10 Codes
Weakness as late effect of stroke (disorder)	<ul style="list-style-type: none"> • I69.398 Other sequelae of cerebral infarction • R53.1 Weakness

Lab Analytes & Panels

Additions and Updates

- 14Q32 IGH FISH nomenclature
- Abs neut confirmed
- AFB body site
- AFB culture source
- Albumin, urine, mg/TV
- Albumin, urine timed, mg/dL
- Albumin, urine excretion rate, mcg/min
- APRI index
- Auto diff confirmed
- CALR %
- CALR amino acid
- CALR nucleotide
- CALR result
- Coproporphyrin (CP) I, ug/L
- Coproporphyrin (CP) III, ug/L
- del(9p) CDKN2A FISH nomenclature
- del(9p) CDKN2A FISH interpretation
- DPYD director review
- DPYD genotype
- DPYD information
- DPYD metabolic activity
- E12-15 result
- E12-15 %
- E12-15 nucleotide
- E12-15 amino acid
- E12-15/CALR/MPL background
- Factor H auto Ab, Unit/mL
- FISH, MPN/CML targetgene result
- FISH, MPN/CML targetgene PDF
- Heptacarboxyl (7-CP), ug/L
- Herpesvirus 7 IgG Ab, IFA
- Hexacarboxyl (6-CP), ug/L
- IHC PD-L1
- JAK2 mutation MPL, %
- Lysosomal enzyme screen
- MPL %
- MPL amino acid
- MPL nucleotide
- MPL result
- NGS methodology
- NGS review
- Paraprotein excret/24hr UPE, mg/24 hr
- Paraprotein UPE, %
- Pentacarboxyl (5-CP), ug/L
- Rh(Du)
- Slide review required
- Tacrolimus II, ng/mL
- Uroporphyrins (UP), ug/L
- Volume for microscopic (ua), mL
- Albumin timed urine panel
- ctDNA Signatera
- Factor H auto Ab panel
- FISH, MPN/CML targetgene panel
- FoundationOne PD-L1 panel
- HHV 7 IgG Ab panel
- Lysosomal enzyme screen panel
- NGS JAK2 E12-15/CALR/MPL panel
- Porphyrins, Qn, random urine panel
- Porphobilinogen, random urine, quant panel

Medications

Additions

- ABBV-151 invest IV
- ART6043 invest Oral
- ARV-471 invest Oral
- CLR 131 invest IV
- DS-6000a invest IV
- Elacestrant dihydrochloride invest Oral
- EO-3021 invest IV
- EP0062 invest Oral
- Livmoniplimab invest (ABBV-151 invest IV)
- SGN-BB228 invest IV
- Tirzepatide Sodium-Pyridoxine Hydrochloride Subcutaneous
- XmAb662 invest IV

Updates

Medication	Update
ARX788 invest IV	New Form available: 10 mg/mL frozen liquid
BA3021 invest IV	New Synonym available: Ozuriftamab Vedotin invest
Disitamab Vedotin (RC48-ADC) invest IV	New Form available: 45 mg recon soln (set as default)
KIN-2787 invest Oral	New Forms available: <ul style="list-style-type: none"> • 50 mg tablet • 200 mg tablet
Niacinamide Oral	New Default Dose available: 500 mg
Nystatin Oral Suspension	Retired Quick Sigs Instructions with “swish and spit.”
Opium Oral Tincture	New Quick Sig available: 0.5 mL by mouth every 4 hours prn diarrhea
Promacta (Eltrombopag Oral)	New Instructions available: Take on an empty stomach, 2 hrs before or 4 hrs after food or calcium products.

Regimen Library

Additions

Biosimilar Addition

This release contains the inclusion of a new bevacizumab biosimilar (Vegzelma) into all applicable regimen templates.

Regimen Name	Problem Group
Albumin (Hypoalbuminemia) Supportive Care	All Problems
BCG (TICE) (Intravesicular) Maintenance D1,8,15 Q84D fb Q168D (Part 1 of 2)	Bladder Cancer, Renal Pelvis and Ureter Cancer, Urethral Cancer
BCG (TICE) (Intravesicular) Maintenance D1,8,15 Q84D fb Q168D (Part 2 of 2)	Bladder Cancer, Renal Pelvis and Ureter Cancer, Urethral Cancer
Docetaxel + Oxaliplatin + Bevacizumab Q21D	Fallopian Tube Cancer, Ovarian and Primary Peritoneal Cancer
Epcoritamab-bysp SQ D1,8,15,22 fb D1,15 fb D1 Q28D	Lymphoma, Non-Hodgkin (NHL) (Parent)
Mirvetuximab soravtansine-gynx + Bevacizumab Q21D	Fallopian Tube Cancer, Ovarian and Primary Peritoneal Cancer
Olaparib + Abiraterone + Prednisone Q30D	Prostate Cancer
Pembrolizumab (Dose Banding) + Lenvatinib Q42D	Melanoma, Skin, Renal Cell Carcinoma (RCC), Uterine Cancer (Parent)
Pembrolizumab Q42D (Dose Banding) (Adjuvant Breast)	Breast Cancer
Pemetrexed + Carboplatin + Bevacizumab Q21D (Mesothelioma)	Malignant Mesothelioma, Malignant Pleural Mesothelioma
Ribociclib D1-21 + Anastrozole Q28D (Adjuvant)	Breast Cancer
Ribociclib D1-21 + Letrozole Q28D (Adjuvant)	Breast Cancer

Updates

Regimens for the following diagnoses have been updated based on the Collaborative Care Committee voting. Changes include but are not limited to reference update, drug infusion instruction updates, renaming of regimens, premedication template updates and number of cycles.

- All Problems
- Amyloidosis
- Brain Tumor (Parent)
- Breast Cancer

- Cervical Cancer
- Colon Cancer
- Fallopian Tube Cancer
- Hepatocellular Carcinoma (HCC)
- Immune Thrombocytopenia Purpura (ITP)
- Leukemia, Chronic Lymphocytic (CLL)
- Lung Cancer, Non-small Cell (NSCLC)
- Lymphoma, Non-Hodgkin (NHL) (Parent)
- Malignant Mesothelioma
- Malignant Pleural Mesothelioma
- Ovarian and Primary Peritoneal Cancer
- Polycythemia Vera
- Rectal Cancer
- Renal Cell Carcinoma (RCC)
- Uterine Cancer (Parent)
- Waldenstrom's Macroglobulinemia

Research

Updates

	Updated Reference Information			
		Updated Drug Service Order Information		
			Updated Regimen Instructions	
				Other Changes
USOR 20289	X	X	X	Now available: USOR 20289 SEA-TGT + Brentuximab Vedotin Q21D
USOR 20305	X	X		
USOR 20307	X	X		
USOR 21173	X			Now available: <ul style="list-style-type: none"> • USOR 21173 AZD9833 or Placebo (Daily) + Ribociclib (D1-21) + Anastrozole or Placebo (Daily) Q28D • USOR 21173 AZD9833 or Placebo (Daily) + Ribociclib (D1-21) + Letrozole or Placebo (Daily) Q28D
USOR 21225	X	X	X	
USOR 21270	X	X	X	No longer available: USOR 21270 ZN-c3 (Continuous Dosing) Q21D
USOR 21287	X	X	X	
USOR 21507	X	X	X	
USOR 21507	X	X	X	
USOR 21550	X			
USOR 22035	X	X	X	
USOR 22041	X	X	X	Now available: USOR 22041 Repriming Cycle Epcoritamab SC D1,8,15,22

	Updated Reference Information		
	Updated Drug Service Order Information		
	Updated Regimen Instructions		
	Other Changes		
USOR 22074	X	X	X
USOR 22147	X	X	X

Billing & HCPCS Codes

Please visit CMS's website for a complete list of **July 2023** [HCPCS Quarterly](#) updates.

Updates

Medication	HCPCS Codes
Acetaminophen IV	J0137 per 10 mg
Allopurinol IV	J0206 per 1 mg
Aztreonam IV, IM, Intraperitoneal	J0457 per: <ul style="list-style-type: none"> • 100 mg • 0.1 gm
Bendamustine IV: DOS 4/1/23-6/30/23	J9999 per 1 mg
Bendamustine IV [Apotex]: DOS 7/1/23-12/31/9999	J9058 per 1 mg
Bendamustine IV (Baxter)	J9059 per 1 mg
Bendamustine IV (Vivimusta)	J9056 per 1 mg
Bupivacaine IV	J0665 per 0.5 mg
Buprenorphine Subcutaneous ER Solution (Brixadi Monthly)	Q9991 per 24 mg
Buprenorphine Subcutaneous ER Solution (Brixadi Weekly)	Q9991 per 24 mg
Clindamycin IV	J0736 per 300 mg
Clindamycin (Baxter)	J0737 per 30 mg
Epcoritamab-bysp (Epkinyly)	J3590 per: <ul style="list-style-type: none"> 8 mg 48 mg

Medication	HCPCS Codes
Esmolol IV	J1805 per 10 mg
Esmolol IV (wg critical care)	J1806 per 10 mg
Factor IX Human (Recom Thr148) IV	J7213 per 1 unit
Fecal Microbiota, Live-jslm Enema	J1440 per 1mL
Furosemide Subcutaneous	J1941 per 20 mg
Immune globulin, Gamma (IgG)-ifas IV	J1576 per 500 mg
Insulin Aspart (niacinamide) Continuous Subcutaneous Infusion (Fiasp)	J1811 per 50 UNITS (For administration through dme (i.e., insulin pump)) J1812 per 5 units
Insulin Aspart (niacinamide) IV (Fiasp)	J1811 per 50 UNITS (For administration through dme (i.e., insulin pump)) J1812 per 5 units
Insulin Aspart (niacinamide) Subcutaneous (Fiasp)	J1811 per 50 UNITS (For administration through dme (i.e., insulin pump)) J1812 per 5 units
Insulin Aspart (niacinamide) Subcutaneous Pen (Fiasp FlexTouch)	J1812 per 5 units
Insulin Aspart (niacinamide) (Lyumjev)	J1813 per 50 UNITS (For administration through dme (i.e., insulin pump)) J1814 per 5 units
Insulin Lispro-aabc Subcutaneous Pen 100 unit/mL (Lyumjev Kwikpen)	J1814 per 5 units
Labetalol IV	J1920 per 5 mg J1921 per 5 mg
Lendacapavir Subq	J1961 per 1 mg
Metronidazole IV	J1836 per 10 mg
Mirvetuximab soravtansine-gynx IV	J9063 per 1 mg
Mosunetuzumab-axgb IV	J9350 per 1 mg
Nitroglycerin IV	J2305 per 5 mg
Paliperidone IM (3-month, 6-month)	J2427 per 1 mg
Phenylephrine IV, IM, Subq	J2371 per 20 mcg

Medication	HCPSC Codes
Posluma (Flotufolastat F 18 Gallium)	A9597 per: <ul style="list-style-type: none"> • 296 MBq • 8 MCi
Remimazolam IV	J2249 per 1 mg
Teclistamab-cqyv Subcutaneous	J9380 per 0.5 mg
Teplizumab-mzww IV	J9381 per 5 mg
Tirzepatide Subcutaneous Pen Injector (Mounjaro)	J3490 per 7.5 mg
Tremelimumab-actl IV	J9347 per 25 mg
Ublituximab-xiyy IV	J2329 per 1 mg
Vasopressin IV (am reg)	J2599 per 1 unit
Vasopressin Continuous Intra-Arterial Infusion	J2598 per 1 unit
Vasopressin Endotracheal	J2598 per 1 unit
Vasopressin IV	J2598 per 1 unit
Vasopressin Intraosseous	J2598 per 1 unit
Vasopressin IM	J2598 per 1 unit
Vasopressin Subcutaneous	J2598 per 1 unit

HCPSC & NDC Crosswalk

Additions

Effective July 1, 2023, unless noted by DOS.

Medication (Brand)	HCPSC Code	NDC
Acetaminophen (Hikam)	J0137 per 10 mg	00143938601 00143938610
Bendamustine: DOS 4/1/23-6/30/23	J9999 per 1 mg	60505622800
Bendamustine (Apotex)	J9058 per 1 mg	60505622800
Bendamustine (Baxter)	J9059 per 1 mg	10019007901
Bendamustine (Vivimusta)	J9056 per 1 mg	71225012001
Clindamycin	J0736 per 300 mg	25021011502 00781328891 67457081504

Medication (Brand)	HCPCS Code	NDC
		00781328909 00781328991 00781329009 00009090218 72572007624 67457081402 25021011504 67457081500 63323028204 63323028206 63323028260 00009305102 25021011551 63323028202 00009509506 00009087021 72572007601 00009077526 67457081400 00009077520 67457081600 00009090211 00009407303 00009072805 72572007424 67457081606 00009509505 00009407304 00781328809 72572007401 25021011506 00009305101 00009087026 00009072809
Clindamycin (Baxter)	J0737 per 300 mg	00338411450 43066099524 43066099324 00338955350 00338954524 00338955324 00338361624 00338954924 00338361250 00338411424 00338954950 00338381450 00338381424 00338361650 00338341024

Medication (Brand)	HCPCS Code	NDC
		00338341050 00338361224 00338954550
Esmolol (wg crit care)	J1806 per 10 mg	44567081210 44567081110
Insulin Aspart (Fiasp)	J1811 per 50 UNITS (For administration through dme (i.e., insulin pump)) J1812 per 5 UNITS	00169320111
Insulin Aspart (Fiasp flex touch)	J1812 per 5 UNITS	00169320515 00169320415 00169320511
Insulin Aspart (Lyumjev)	J1813 per 50 units ((For administration through dme (i.e., insulin pump)) J1814 per 5 units	00002772801
Insulin Lispro-aabc (Lyumjev KwikPen)	J1814 per 5 units	00002822827 00002820701 00002820705 00002822801 00002823501 00002823505
Labetalol	J1920 per 5 mg	36000032010 00143936610 72266010201 36000032001 70092100944 25021031740 70004070028 00143936601 72611073801 70092101044 70092155844 70092155944 70092200944 36000032402 00143962201 00641625201 00641625210 25021031720 72266010341 72611073401 47781058629 47781058656 65302050304 36000032401

Medication (Brand)	HCPCS Code	NDC
		36000032202 36000032201 69374094604 69374094634 72572035001 70004070006 00409226754 00143962301 00143932001 72266010301 00409226720 00409233934 00409233924
Labetalol (Hikma)	J1921 per 5 mg	00143936510 00143936501 00143936410 00143936310 00143936301 00143936401
Metronidazole	J1836 per 10 mg	47335099301 25021013182 00409781137 00409781111 00409015224 00409015201 00338954124 00338105548 00264553532
Paclitaxel-Protein Bound (American Regent): DOS 4/1/23-6/30/23	J9999 per 1 mg J9259 per 1 mg	00517430001
Pemetrexed	J9323 per 10 mg	00409218801 00409353201 00409104501
Pemetrexed (Bluepoint)	J9322 per 10 mg	68001055141 68001055041
Vasopressin (American Regent)	J2599 per 1 unit	00517102001